controlled drug substance

(redirected from Controlled drug substances)

controlled drug substance

Any drug or therapeutic agent–commonly understood to include narcotics, with a potential for abuse or addiction, which is held under strict governmental control, as delineated by the Comprehensive Drug Abuse Prevention & Control Act passed in 1970
Controlled drug substances
Schedule I drugs High abuse potential, no accepted medical use in US–Acetorphine, acetyl methadol, allyprodine, α—acetylmethadol, bufotenine, dextromoramide, diethyltryptamine, dimethyltryptamine–DMT, etorphine, heroin, ibogaine, ketobemidone, LSD–N,N-diethyl-D-lysergamide or lysergic acid diethylamide, marijuana, mescaline, PCP–phencyclidine, peyote, phenadoxone, phenampromide, racomoramide, tetrahydrocannibol
Schedule II High abuse potential, potentially leading to severe psychologic or physical dependence; schedule II agents have acceptable medical uses, eg narcotics–alphaprodine, anileridine, cocaine, codeine, diphenoxylate, diprenorphine, etorphine HCl, ethymorphine, hydrocordone, hydromorphone, levorphanol, meperidine, methadone, morphine, oxymorphone, poppy straw concentrates, powdered opium, raw opium, thebaine and non-narcotics–amphetamine, amobarbital, methaqualone, methamphetamine, methaqualone, pentobarbital, percodan, phencyclidine, phenmetrazine, secobarbital
Schedule III High abuse potential, moderate to low physical dependence, and high psychologic dependence potential, with acceptable medical uses, which may be narcotic–eg nalorphine, paregoric, or nonnarcotic–eg aprobarbital, benzphentamine, butabarbital, chlorphentermine, chlortermine, glutethimide, mazindol, methyprylon, phendimetrazine, probarbital, talbutal, thiamylal, thiopental, vinbarbital
Schedule IV Minimal abuse potential, limited physical or psychological dependence potential, nonnarcotic, eg barbital, chloral hydrate, chlordiazepoxide, clonazepam, chlorazepate, dextropropoxyphene, diazepam, diethylpropion, ethchlorvynol, ethinamate, fenfluramine, lorazepam, mebutamate, methobarbital, meprobamate, methohexital, oxazepam, paraldehyde, phenobarbital, phentermine, prazepam
Schedule V Very low abuse/dependence potential–eg brown mixture–opium, some codeine preparations, diphenozylate preparations–Lomotil, ethylmorphine-Cidicol, opium–Donnagel-PG, terpin hydrate, or non-narcotic, eg loperamide
References in periodicals archive ?
The acquisition of Epic provided a robust generic product portfolio, which includes tablets, two-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances and softgel caps.
This acquisition complemented PuraCap's own research and development efforts by utilizing Epic's strengths in the manufacture and development of controlled drug substances and powder formulations.
The deal was made to complement PuraCap's existing research and development capabilities with Epic's experience in manufacturing and developing controlled drug substances and powder formulations.
Humanwell and PuraCap will acquire Epic's balanced and diversified range, which includes 15 marketed generic products and a range of 37 products, and this acquisition will complement PuraCap's own R&D efforts by using Epic's strengths in the manufacture and development of controlled drug substances and powder formulations.
The acquisition of Epic will provide a generic product portfolio which includes tablets, two-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances.
Humanwell and PuraCap will acquire Epic's portfolio, which currently consists of 15 marketed generic products and a pipeline of 37 products, and this acquisition will complement PuraCap's own R/D efforts by utilising Epic's strengths in the manufacture and development of controlled drug substances and powder formulations.
The acquisition of Epic provides a robust generic product portfolio which includes tablets, 2-piece capsules and powder dosage form products as well as a future product portfolio that will include a series of controlled drug substances and soft-gel caps.

Full browser ?